NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $169.14 +0.28 (+0.17%) Closing price 04:00 PM EasternExtended Trading$170.50 +1.36 (+0.80%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neurocrine Biosciences Stock (NASDAQ:NBIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neurocrine Biosciences alerts:Sign Up Key Stats Today's Range$166.56▼$169.5050-Day Range$135.13▼$169.1452-Week Range$122.14▼$186.12Volume1.06 million shsAverage Volume1.48 million shsMarket Capitalization$17.12 billionP/E Ratio21.16Dividend YieldN/APrice Target$202.32Consensus RatingModerate Buy Company Overview Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children. Neurocrine primarily serves the U.S. market, while partnerships support the development or commercialization of certain products in other regions. Kyle Gano became the company’s chief executive officer in 2025, succeeding Kevin Gorman.AI Generated. May Contain Errors. Read More Neurocrine Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreNBIX MarketRank™: 4.89901016586 of 5 starsNeurocrine Biosciences scored higher than 98% of companies evaluated by MarketBeat, and ranked 9th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 19 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialNeurocrine Biosciences has a consensus price target of $202.32, representing about 19.6% upside from its current price of $169.14.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth17.60% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 17.60% in the coming year, from $8.41 to $9.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 21.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 21.16, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.09.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 0.68. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.11% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Neurocrine Biosciences has recently decreased by 8.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.62 News SentimentNeurocrine Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Neurocrine Biosciences this week, compared to 8 articles on an average week.Search Interest12 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,829,332.00 in company stock.Percentage Held by Insiders4.60% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBIX Stock News HeadlinesNeurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare ConferenceNovember 10 at 4:01 PM | prnewswire.comNeurocrine Biosciences (NASDAQ:NBIX) & Silo Pharma (NASDAQ:SILO) Head-To-Head ComparisonNovember 10 at 3:45 AM | americanbankingnews.comBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 10 at 1:00 AM | Base Camp Trading (Ad)Neurocrine Biosciences Earnings Call Signals Broad GrowthNovember 9 at 7:30 PM | tipranks.comNeurocrine Biosciences (NASDAQ:NBIX) Upgraded to "Buy" at Wall Street ZenNovember 7 at 2:51 AM | americanbankingnews.comNeurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) CapsulesNovember 5, 2026 | prnewswire.comNeurocrine Biosciences: Breaking Down A Solid QuarterNovember 5, 2026 | seekingalpha.comNeurocrine Biosciences (NASDAQ:NBIX) Director Sells $44,700.00 in StockNovember 4, 2026 | insidertrades.comSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $141.83 at the beginning of the year. Since then, NBIX stock has increased by 19.3% and is now trading at $169.14. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its earnings results on Monday, November, 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. The business's quarterly revenue was up 41.3% compared to the same quarter last year. Read the conference call transcript. How will Neurocrine Biosciences' stock buyback program work? Neurocrine Biosciences' Board of Directors approved a stock buyback plan on Friday, February 21st 2025, which authorizes the company to buy back $500 million in shares, according to EventVestor. This means that the company could purchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional investors include Aberdeen Group plc (1.17%), Ninety One UK Ltd (0.43%), Pictet Asset Management Holding SA (0.39%) and Russell Investments Group Ltd. (0.38%). Insiders that own company stock include Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Darin Lippoldt, Matt Abernethy, Eric Benevich, William H Rastetter, Richard F Pops, Jude Onyia, Eiry Roberts, Julie Cooke, Ingrid Delaet, Stephen A Sherwin, David W Boyer and Shalini Sharp. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Walt Disney (DIS), AbbVie (ABBV), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Company Calendar Last Earnings11/02/2026Today11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NBIX's financial health is in the Red zone, according to TradeSmith. NBIX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NBIX CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees2,000Year Founded1992Price Target and Rating Average Price Target for Neurocrine Biosciences$202.32 High Price Target$253.00 Low Price Target$150.00 Potential Upside/Downside+19.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$6.74 Trailing P/E Ratio21.16 Forward P/E Ratio17.10 P/E Growth0.68Net Income$478.60 million Net Margins18.98% Pretax Margin25.18% Return on Equity23.39% Return on Assets16.22% Debt Debt-to-Equity RatioN/A Current Ratio2.04 Quick Ratio1.97 Sales & Book Value Annual Sales$2.86 billion Price / Sales5.99 Cash Flow$5.02 per share Price / Cash Flow33.69 Book Value$38.32 per share Price / Book4.41Miscellaneous Outstanding Shares101,220,000Free Float96,563,000Market Cap$17.12 billion OptionableOptionable Beta0.36 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:NBIX) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
